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The purpose of this present study was to evaluate the serum levels of ET-1 and TGF-β in the newborns with respiratory distress.
In this study, newborns with respiratory distress hospitalized into the Newborn Intensive Care Unit were included. The highest
values of ET-1 and TGF-β were obtained from newborns with diagnosis as meconium aspiration syndrome (5.70 ± 5.87 pg/mL
and 3.75 ± 1.94 pg/mL, resp) in the sample obtained in the ﬁrst six hours after birth, and these are statistically diﬀerent from
control group (P<. 05). Also, same results were obtained for newborns with respiratory distress syndrome (3.37 ± 1.59 pg/mL
and 2.05 ± 0.98 pg/mL, resp). After oxygen treatment, ET-1 values obtained in the ﬁrst six hours of life were decreased regularly
in the following days (P<. 05). In the diﬀerentiating diagnosis of the respiratory distress of newborns, the investigation of ET-1
and TGF-β levels is meaningful. The ET-1 levels investigated in the ﬁrst six hours is more useful in determining the prognosis, and
repeating ET-1 levels in the following days is more meaningful to determine clinical response.
Copyright © 2006 Derya Benzer et al. This is an open access article distributed under the Creative Commons Attribution License,
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
INTRODUCTION
Respiratorydistresscontinuestoaccountforsigniﬁcantmor-
tality and morbidity in the Neonatal Intensive Care Unit. At
birth, pulmonary vascular resistance decreases with initia-
tion of ventilation. Respiratory distress syndrome (RDS) in
premature infants is caused by a structural immaturity of
lungs and the insuﬃcient production of surfactant and its
incidenceisinverselyrelatedtogestationalage[1].Theprob-
lems concerning to the respiratory system prolonge the hos-
pitalization period in the premature infants [2].
Endothelin (ET) is a peptide of 21 amino acids in chain
with two disulﬁde bonds with three distinct isoforms: ET-
1, ET-2, and ET-3 [3]. Endothelin causes isolated contrac-
tion of pulmonary veins, vascular smooth muscle mitoge-
nesis, myocardial cell hypertrophy, positive innotropic and
chronotropic eﬀects, bronchoconstriction, mucous secre-
tion, cellular proliferation, and inﬂammatory reactions [4].
Hypoxia, stress, antidiuretic hormone, and the secretion of
some mediators stimulate its synthesis. Clinical investiga-
tions have shown increased plasma concentrations of ET-1
during RDS and in case of pulmonary hypertension of other
origins. But it is unclear whether ET-1 is actually responsi-
ble for the pulmonary hypertension, or the increased ET-1
plasma concentration is a result of the pulmonary hyperten-
sion that originated otherwise [5–8].
Also transforming growth factor beta (TGF-β)i saf a m -
ily of three isoforms that regulate cell growth and diﬀeren-
tiation, extracellular matrix sythesis cytokines production,
and vascular neogenesis [9]. The increase in TGF-β precedes
thedevelopmentofpulmonaryhypertensionwhichincreases
circulating ET-1 levels in animals. TGF-β induces ET-1 gene
expression and ET-1 peptide synthesis in bovine pulmonary
artery endothelial cells [10, 11]. The cells responsible for in-
creased ET-1 sythesis during hypoxia are unclear, and short-
term eﬀects of hypoxia raise plasma ET-1 levels in animal
models; whether chronic hypoxia would lead to diﬀerent re-
sults is unknown [12].
Experimental studies have suggested that ET-1 plays an
important role in pulmonary vascular reactivity in neona-
tal RDS. There is also an elevation of ET-1 in tracheal as-
pirates from these infants [13]. TGF-β showed the strongest
stimulatory eﬀect on ET-1 and gene transcription in vascular
smooth muscular cells [14]. There are few studies measuring
ET-1 and no study measuring TGF-β by enzyme immunoas-
saywithaverysmallnumberofhumanprematurenewborns
suggesting that ET-1 is elevated in RDS.2 Mediators of Inﬂammation
Table 1: Demographic characteristics of the patient and control groups.
RDS RDS-2 MAS Total Control group
Gestational age ———— —
Premature 6 283 7 3 9
Mature —1 61 1 2 7 1 1
Total 62 24 14 100 20
Gender ———— —
Female 24 11 7 42 6
Male 38 13 7 58 14
Total 62 24 14 100 20
Birth weight (g) 1367 ±368 2633 ±577 2989 ±914 1898 ±864 2575 ±863
Thepurposeofthispresentstudyistoevaluatetheserum
levels of ET-1 and TGF-β in the newborns with respiratory
distress (diagnosis as RDS, as transient tachypnea (RDS-2),
and as meconium aspiration syndrome (MAS)), to investi-
gatethemeaningfulnessoftherepetitivevaluesofET-1inthe
followup of these diseases, and to determine the reﬂection of
serum ET-1 level on the mortality at the ﬁrst six hours after
birth.
MATERIALS AND METHOD
In this study, newborns with respiratory distress hospital-
ized into the Newborn Intensive Care Unit were included.
The study group was evaluated by 100 newborns, 62 diag-
nosed as RDS, 24 as RDS-2, and 14 as MAS within the last
six months. Moreover, a control group was evaluated with 20
healthy newborns. For the study, written permits were taken
f r o mt h ep a r e n t so fe a c hn e w b o r n ,a sw e l la sa na p p r o v a lo f
the regional Ethics Comittee.
A detailed history of each infant was obtained. The ges-
tational age of the newborns was determined according to
the New Ballard Score [15]. According to the gestational age,
newborns younger than 38 weeks were classiﬁed as prema-
ture and newborns between 38–42 weeks as mature. After
a detailed physical examination, the newborns were inves-
tigated with respect to their blood gases, complete blood
count, full blood biochemistry, and C-reactive protein levels,
and their culture samples were taken.
Moreover,ﬁrstbloodsampleswereobtainedfromallpre-
mature and mature sick or healthy newborns in the ﬁrst six
hours after birth. The serum was collected into polypropy-
lene tube and centrifuged immediately and was stored at
−70◦C. In addition, repetitive blood samples were obtained
at the third, 7th, 14th, and 28th day from the patients whom
oxygen supply continued. These serums were also stored at
−70◦C. Then, the samples were resolved and they were stud-
ied with ELISA method in the Immunology Laboratory.
PlasmaTGF-βlevelwasdeterminedbycaptureELISAac-
cording to the instructions of R & D Systems using mon-
oclonal antihuman TGF-β, R & D Systems, Inc (USA). In
brief, 100μL of the capture antibody was transferred to an
ELISA plate and incubated overnight at room temperature.
Each well was then washed three times with wash buﬀer. Af-
ter removal of the buﬀer, the plates were blocked by adding
300μL of PBS containing 5% tween 20, 5% sucrose, and
0.05%NaN3 toeachwellandincubatedatroomtemperature
for a minimum of 1 hour. 100μL of blood plasma sample per
wellwasadded,theELISAplatewascoveredwithanadhesive
strip and incubated 2 hours at room temperature. 100μLo f
streptavidin HRP (R & D Systems, Catalog # DY998, 1/200
in appropriate diluent) was added to each well; the plate was
covered and incubated for 20 minutes at room temperature.
After subsequent addition of substrate solution and stop so-
lution (both from R & D Systems, Inc), the optical density
of each well was determined within 30 minutes, using a mi-
croplate reader set to 450nm.
All samples for ET-1 measurement were tested in du-
plicate. ET-1 was determined by an enzyme immunoassay
(QuantiGlo Human ET-1, R & D Systems, Inc, Minneapo-
lis, Minn, USA). The minimum detectable dose of ET-1 was
0.16pg/mL, with intra- and interassay coeﬃcients of varia-
tion of 2.5a n d5 % ,r e s p e c t i v e l y .
Statistical evaluations were made by means of SPSS 11.0
package program. All the results were given primarily as
medium and standard deviation. Moreover, in the diﬀeren-
tial diagnosis the meaningfulness of the ET-1 and TGF-β val-
ues was investigated using the Scheﬀea n dT u k e yp o s th o c
tests, in the followup, the diﬀerences of the ET-1 levels were
investigated using the Kruskal-Wallis variance analysis. In all
of the results P<. 05 was accepted as meaningful.
RESULTS
The newborns comprimising the study group had a gesta-
tional age between 28–42 weeks. From all of the patients 62
(62%) newborns were diagnosed as RDS and all of them
were premature. Of 24 newborns with RDS-2 diagnosis 16
(67%) were mature and of 14 newborns with MAS diagnosis
11 (79%) were mature. In the control group, only 11 (55%)
newborns were mature (Table 1). Male predominance with a
percentage of 61% was determined in the group with RDS,
and weight results were considerably lower due to prematu-
rity (1367 ±368g).
Plasma endothelin-1 and TGF-β concentrations of the
mature newborns in the control group were measured as
0.77 ± 0.56pg/mL and 0.25 ± 0.41pg/mL, respectively, and
did not show a signiﬁcant diﬀerence according to the gesta-
tional age (P>. 05) (Figure 1).Derya Benzer et al 3
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Figure 1:PlasmaET-1concentrationsofthehealthyprematureand
mature newborns were 0.79 ± 0.44 and 0.77 ± 0.56pg/mL, respec-
tively.Thisdiﬀerencewasnotsigniﬁcant(P>. 05).AlsoTGF-βcon-
centrations in this group were 0.17 ± 0.37 and 0.25 ± 0.41pg/mL,
respectively, and was not signiﬁcantly diﬀerent (P>. 05).
Plasma endothelin-1 and TGF-β concentrations of the
newborns with diﬀerent diagnosis measured in the ﬁrst six
hours of life are summarized in Figure 2. In the description
of the eﬀectiveness of the treatment and in the early de-
termination of the prognosis plasma ET-1 and TGF-β con-
centrations in newborns with MAS diagnosis were deter-
mined as 5.70±5.87pg/mL and 3.75±1.94pg/mL, and with
RDS diagnosis were determined as 3.37 ± 1.59pg/mL and
2.05 ± 0.98pg/mL. According to the control group, plasma
ET-1 and TGF-β concentrations of the newborns with res-
piratory distress were determined to be statistically higher
(P<. 05).
With the oxygen supply, it was observed that plasma ET-
1 concentrations of the newborns obtained in the ﬁrst six
hours of life are desposed to decrease regularly in the follow-
ing days (Figure 3). In the same way, plasma ET-1 concen-
trations obtained in the ﬁrst six hours and repetitive plasma
ET-1 concentrations in the following days were statistically
higher in the newborns who died later compared to the sur-
vivors (P<. 05) (Figure 4).
DISCUSSION
Respiratory distress is a major problem in the newborns and
diﬀerent reasons cause this problem. Among those, the most
frequent ones are RDS; a problem of premature newborns,
and the others are RDS-2 and MAS; a problem of mature
newborns. In this study, diseases causing respiratory distress
after birth in the early period were evaluated, and RDS was
the most frequent (62%).
Endothelin-1 and TGF-β levels, the vascular factor, and
material of respiratory distress were investigated. In the
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Figure 2: ET-1 concentrations according to diagnosis in the sick
newborns at the sixth hour after birth were 3.37 ± 1.59pg/mL in
RDS, 1.60 ± 0.6 6p g / m Li nR D S - 2 ,5 .70 ± 5.87pg/mL in MAS, and
0.78±0.50pg/mL in healthy group. Only the concentrations of ET-
1 in RDS and MAS groups were signiﬁcantly diﬀerent (P<. 05).
Also plasma TGF-β concentrations were 2.05 ±0.98pg/mL in RDS,
1.59 ±0.66pg/mL in RDS-2, 3.75 ±1.9 4p g / m Li nM A Sa n d0 .22 ±
0.39pg/mL in healthy group. Only the diﬀerence in RDS and MAS
group was signiﬁcant (P<. 05).
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Figure3:ChangesoftheplasmaET-1(pg/mL)concentrationsdur-
ing the oxygen treatment days in the diﬀerent dignostic newborns
tended to decrease. The plasma ET-1 concentrations in the sixth
houroflifeweredecreased atthirddayas2.80±1.49pg/mL inRDS,
1.28 ±0.84pg/mL in RDS-2, and 3.69 ±2.13pg/mL in MAS group.
This values also was signiﬁcantly diﬀerent as (P<. 05). Values at the
seventh and simultaneous days were also decreased.4 Mediators of Inﬂammation
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Figure 4: ET-1 concentrations in the newborns who died were 4.44 ± 1.26pg/mL in RDS and 11.60 ± 8.97pg/mL in MAS groups (P<. 05)
a n di nt h o s ew h os u r v i v e dw e r e2 .42 ± 1.19pg/mL in RDS and 3.41 ± 1.31pg/mL (P<. 05) at the sixth hour of life. ET-1 concentrations
in the newborns who died were 3.70 ± 1.31pg/mL in RDS and 7.30 ± 0.00pg/mL in MAS group (P<. 0 5 )a n di nt h o s ew h os u r v i v e dw e r e
2.04 ± 1.20pg/mL in RDS and 2.77 ± 0.73pg/mL (P<. 05) at the third day of life. ET-1 concentrations in the newborns who died were
3.42 ± 1.2 7p g / m Li nR D Sa n d7 .00 ± 0.0 0p g / m Li nM A Sg r o u p( P<. 0 5 )a n di nt h o s ew h os u r v i v e dw e r e1 .82 ± 1.15pg/mL in RDS and
1.60 ± 0.00pg/mL (P<. 05) at the seventh day of life. ET-1 concentrations in the newborns who died were 3.03 ± 0.95pg/mL and in those
who survived were 1.60 ±1.35pg/mL in RDS (P<. 05) at the 14th day of life.
control and patient groups’ plasma, ET-1 and TGF-β con-
centrations were statistically diﬀerent. The highest value was
obtained in the newborns with MAS and the others were or-
dered as RDS, RDS-2, and the healthy newborns.
Kaapaetal[16]inasimilarstudyfoundthatplasmaET-1
concentrationswerenotcorrelatedwiththepulmonarypres-
sure but that high plasma concentrations of ET-1 reﬂected
severe pulmonary damage. In another study, there was a sig-
niﬁcantly higher ET-1 concentration in newborns with pul-
monary hypertension than healthy newborns or newborns
with RDS [17]. In contrast of our study, Kuo et al [18]d e t e r -
mined the highest values of plasma ET-1 concentrations in
the ﬁrst six hours of life in the newborns diagnosed as RDS,
and the newborns diagnosed as MAS had a second high-
est values of ET-1 concentrations. Like our study, Kojima et
al [19] found out that plasma ET-1 concentrations in new-
borns with RDS were higher compared to the newborns with
RDS-2. A study of Benjamin et al [20] demonstrated that in-
fants with and without RDS had similar umbilical cord ET-1
concentrations, whereas ET-1 concentrations were higher in
RDS than in control newborns 18–40 hours after birth. The
increased vascular resistance in RDS may be related to high
plasma ET-1 concentrations.
In an experimental model of RDS in the newborn lamb,
the ET-1 concentration was increased after induction of RDS
concomitant with the development of pulmonary hyper-
tension, from an early time point onwards. Increased ET-
1 concentration during RDS appeared to be reached in the
early phase of pulmonary hypertension development. Also
increased circulating levels of ET-1 were correlated with the
severity of pulmonary hypertension [21].
Whereas, TGF-β is secreted from the alveolar macro-
phages in the lungs, and in case of damage it is responsi-
ble to the organization of the ﬁbrosis growth, inﬂammatory
response, and the recovery of the tissue [22]. For this rea-
son, the TGF-β studies were realized in the patients with
bronchopulmonary displasia, where ﬁbrosis was dominated
[23,24].Inourstudy,accordingtotheresultsofplasmaET-1
levels,theﬁrsthighestlevelsofTGF-β wereinnewbornswith
MAS and the second were in newborns with RDS.
Starting from the moment of the diagnosis, it was ob-
served that ET-1 concentrations of the patients who re-
ceived surfactant and mechanic ventilator supply were de-
creased. Kuo et al [18]a n dN i ue ta l[ 25] emphasized those
plasma ET-1 concentrations of the newborns with and with-
out bronchopulmonar dysplasia did not show any diﬀer-
ence. The endothelium modulates vascular tone by releas-
ing endothelium-derivated vasodilatators, including nitric
oxide, prostacyclin, bradykinin, and vasoconstrictors such
as ET-1 and angiotensin II, in response to a number of
biochemical and physical stimuli. Recent studies have sug-
gested that an imbalance between nitric oxide and ET-1 may
contribute to changes in vascular tone observed in these dis-
eases. A number of vasculopathies associated with an im-
paired bioavailability of nitric oxide have been found to be
linked to enhanced sythesis of ET-1 [26].
In our study, plasma ET-1 concentrations might have a
best indicator of the prognosis in the ﬁrst six hours of life,
but TGF-β concentrations did not have the same eﬀect. be-
causeitwasasigniﬁcantdiﬀerencebetweenthesurvivorsand
dead newborns, in whom ET-1 concentrations were higher
in the ﬁrst six hours of life. These newborns presented severeDerya Benzer et al 5
damage in the lungs, starting from the ﬁrst hour. We did not
see any other study emphasizing this subject in the literature.
As a result, it was decided that, in the diﬀerentiating di-
agnosis of the RDS, RDS-2, and MAS, which are a signiﬁcant
problem of premature and mature newborns, the investiga-
tion of ET-1 and TGF-β concentrations is meaningful, but
that in wider groups, it is required to determine the border-
line values. It was observed that the ET-1 levels investigated
intheﬁrstsixhoursaremoreusefulindeterminingtheprog-
nosis, and the ET-1 concentrations investigated in the fol-
lowing days are more meaningful presenting clinical recov-
ery. In the determination of prognosis, TGF-β concentration
invesitigated in the ﬁrst six hours does not seem meaning-
ful.Sincetheresultsarestillcontradictory,itwasemphasized
that it is required to carry out new researches.
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